Literature DB >> 31758441

Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.

Marion Hemmersbach-Miller1,2, Barbara D Alexander3, Carl F Pieper4, Kenneth E Schmader5,6.   

Abstract

Evaluate risk factors for cytomegalovirus (CMV) reactivation during the first year after kidney transplantation in the CMV-seropositive older recipient. Retrospective single-center study. Between 2011 and 2015, 91 patients ≥ 65 years received a kidney transplant; these were matched with 91 controls, aged 40-60. Risk of CMV reactivation in the CMV-seropositive recipients was analyzed. Sixty-three older and 54 younger recipients were included; 50% had received CMV-directed prophylaxis. CMV reactivation was significantly more frequent in the older group (71.4% vs 44.4%, p = 0.003) and occurred earlier (p = 0.003). A multivariate model showed that only age was associated with CMV reactivation (OR 2.48, p = 0.03). After excluding patients that received thymoglobulin, older age group remained the only risk factor of CMV reactivation (OR 3.81, p = 0.014). Recurrent event analysis showed that the older cohort had an HR of 1.94 (p = 0.01) of CMV viremia; there was significant episode-cohort interaction (p < 0.01). While the older group had a higher risk of infection (HR = 2.43), after the initial episode the relative hazards were approximately equal (HR = 1.08, at period 2). This suggests that it is key to specifically avoid the first episode of reactivation. Universal prophylaxis or a hybrid prophylaxis model should be considered in the CMV-seropositive kidney transplant recipient aged ≥ 65 years.

Entities:  

Keywords:  Cytomegalovirus; Infection; Kidney transplantation; Older adults

Mesh:

Year:  2019        PMID: 31758441      PMCID: PMC7067538          DOI: 10.1007/s10096-019-03744-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  2 in total

1.  Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study.

Authors:  Amit D Raval; Michael L Ganz; Kathy Fraeman; Andrea L Lorden; Shanmugapriya Saravanan; Yuexin Tang; Carlos A Q Santos
Journal:  Transpl Int       Date:  2022-08-12       Impact factor: 3.842

Review 2.  Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response.

Authors:  Eleonora Forte; Zheng Zhang; Edward B Thorp; Mary Hummel
Journal:  Front Cell Infect Microbiol       Date:  2020-03-31       Impact factor: 5.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.